Companion animal vaccines play an important role in improving the health of companion animals in a cost effective manner. These vaccines are also important for reducing viral diseases transmitted from animals to animals or animals to humans. The U.S. FDA Center for Veterinary Medicine (CVM) approves drugs for companion (pet) animals such as dogs, cats, and horses and for food-producing animals such as cattle, pigs, and chickens. Moreover, increasing initiatives from regulatory authorities for prevention of diseases such as viral diseases in companion animals are expected to boost the global companion animal market growth over the forecast period. For instance, in 2016, The American Animal Hospital Association (AAHA) has commissioned a task force of veterinary oncology experts to develop a set of guidelines that will help veterinary teams work with pet owners for tailored treatment plans that will improve the quality of life of pets with cancer.
Market Dynamics
The increasing approval and launch of novel companion vaccines, adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, and rising research and development of novel vaccines are expected to drive the growth of global companion animal vaccine market over the forecast period. For instance, in March 2019, Virbac, a French animal care company, launched a vaccine called CANILEISH to prevent canine leishmaniosis, due to the increasing prevalence of canine leishmaniosis in several regions across the globe, especially in Southern Europe and South America.
Moreover, in June 2018, Zoetis received approval from the U.S. Department of Agriculture for marketing its first monovalent vaccine Fostera Gold PCV, used in the pork industry for swine that includes two genotypes of porcine circovirus type 2 (PCV2).
Key features of the study:
- This report provides in-depth analysis of the global companion animal vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global companion animal vaccine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Ceva, Merck & Co., Inc., Virbac, Zoetis Inc, HIPRA, Biogénesis Bagó, and Ourofino Animal Health.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansions and marketing tactics
- The global companion animal vaccine market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global companion animal vaccine market.
Detailed Segmentation:
- Global Companion Animal Vaccine Market, By Product Type:
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- Global Companion Animal Vaccine Market, By Animal Type:
- Canine
- Feline
- Equine
- Others
- Global Companion Animal Vaccine Market, By Distribution Channel:
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- Global Companion Animal Vaccine Market, By Region:
- North America
- By Product Type
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- By Animal Type
- Canine
- Feline
- Equine
- Others
- By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- By Country
- Latin America
- By Product Type
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- By Animal Type
- Canine
- Feline
- Equine
- Others
- By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- By Animal Type
- Canine
- Feline
- Equine
- Others
- By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- By Animal Type
- Canine
- Feline
- Equine
- Others
- By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- By Animal Type
- Canine
- Feline
- Equine
- Others
- By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type
- Attenuated Live Vaccine
- Conjugate Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- DNA Vaccine
- Recombinant Vaccine
- By Animal Type
- Canine
- Feline
- Equine
- Others
- By Distribution Channel
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institute
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Elanco Animal Health Incorporated *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Boehringer Ingelheim GmbH
- Ceva
- Merck & Co., Inc.
- Virbac
- Zoetis Inc.
- HIPRA
- Biogénesis Bagó,
- Ourofino Animal Health
“*” marked represents similar segmentation in other categories in the respective section.
